Tercica Submits Hormonal Disorder Drug for Approval
Posted on: Friday, 3 November 2006, 06:00 CST
Tercica has said its partner Ipsen submitted a new drug application to the FDA for Somatuline Autogel injection to treat patients with the hormonal disorder acromegaly.
Tercica licensed from Ipsen the rights to develop and market Somatuline Autogel in the US and Canada in a transaction that closed on October 13, 2006.
"Ipsen's submission of the NDA for Somatuline Autogel injection is an important milestone for Tercica as it moves the product closer to potential approval and commercialization in the US," said John Scarlett, CEO of Tercica.
As of December 31, 2005, Somatuline and Somatuline Autogel had marketing authorizations in over 50 countries for the treatment of acromegaly and neuroendocrine tumors. The product is supplied in pre-filled syringes to be injected subcutaneously.
In July 2006 Health Canada approved Somatuline Autogel for the long-term treatment of patients with acromegaly.
The FDA will determine within 60 days whether the submission will be accepted for filing. Tercica expects to launch Somatuline Autogel in Canada in early 2007.
Source: Datamonitor
Related Articles
- Ipsen Completes the Acquisition of Tercica, Inc. In North America, the Third of Its Three Steps to Globalize Its Fast Growing Specialist Care Business
- Tercica Announces Results From Increlex(R) IGFD Patient Registry and Other Increlex(R) Studies at the 90th Meeting of the Endocrine Society
- Ipsen Builds a Fully Fledged Presence in North America, Significantly Enhancing Its Geographic Footprint, Global Specialty Portfolio and Growth Profile
- Ipsen: Somatuline(R) Depot Receives Marketing Approval in the United States for the Treatment of Acromegaly
- Somatuline(R) Depot Receives FDA Marketing Approval for the Treatment of Acromegaly
- Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Accepted for Filing By FDA
- FDA Accepts Acromegaly Drug Filing From Ipsen
- FDA Accepts for Filing a New Drug Application (NDA) for Somatuline(R) Autogel(R)
- Ipsen and Tercica to Enter into Worldwide Strategic Collaboration in Endocrinology
 |
 |
User Comments (0)
RSS Feeds